Abstract
The pharmacological treatment options for obesity are currently very limited but the prevalence of the disease is increasing rapidly. Obesity has many serious sequelae, the most common of which is type-2-diabetes. The benefits of weight loss on health are established but the major impediment to weight loss treatments is maintenance of weight lost over the long term. The reduced- or post-obese individual undergoes physiological changes that are geared towards energy storage and weight regain. One of the physiological changes is a reduced capacity to oxidise fatty acids pushing them through pathways of triacylglycerol synthesis. In this review, some of the past drug treatments aimed at increasing energy expenditure, such as dinitrophenol and ephedrine, are discussed. Current, or nearly current therapies such as sibutramine and rimonabant are also discussed in the context of increased energy expenditure. The main part of the review focuses on future prospects with discussion around a selection of targets with potential in energy expenditure that lie in pathways with AMP-kinase at their centre and ending at the mitochondrion.
Keywords: obesity, energy expenditure, type-2-diabetes
Current Drug Targets
Title: Treating Obesity: Pharmacology of Energy Expenditure
Volume: 5 Issue: 3
Author(s): John C. Clapham
Affiliation:
Keywords: obesity, energy expenditure, type-2-diabetes
Abstract: The pharmacological treatment options for obesity are currently very limited but the prevalence of the disease is increasing rapidly. Obesity has many serious sequelae, the most common of which is type-2-diabetes. The benefits of weight loss on health are established but the major impediment to weight loss treatments is maintenance of weight lost over the long term. The reduced- or post-obese individual undergoes physiological changes that are geared towards energy storage and weight regain. One of the physiological changes is a reduced capacity to oxidise fatty acids pushing them through pathways of triacylglycerol synthesis. In this review, some of the past drug treatments aimed at increasing energy expenditure, such as dinitrophenol and ephedrine, are discussed. Current, or nearly current therapies such as sibutramine and rimonabant are also discussed in the context of increased energy expenditure. The main part of the review focuses on future prospects with discussion around a selection of targets with potential in energy expenditure that lie in pathways with AMP-kinase at their centre and ending at the mitochondrion.
Export Options
About this article
Cite this article as:
Clapham C. John, Treating Obesity: Pharmacology of Energy Expenditure, Current Drug Targets 2004; 5 (3) . https://dx.doi.org/10.2174/1389450043490451
DOI https://dx.doi.org/10.2174/1389450043490451 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Nontraditional Cardiovascular Risk Factors in Pediatric Type 1 Diabetes
Current Diabetes Reviews Dyslipidemia as a Risk Factor for Ischemic Stroke
Current Topics in Medicinal Chemistry Estrogen Receptor 1 Agonist PPT Stimulates Slc2a4 Gene Expression and Improves Insulin-Induced Glucose Uptake in Adipocytes
Current Topics in Medicinal Chemistry Lifestyle Changes and Surgical Treatment for Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Vascular Risk Factors and Neurodegeneration in Ageing Related Dementias: Alzheimer’s Disease and Vascular Dementia
Current Alzheimer Research Microalbuminuria: A Neglected Cardiovascular Risk Factor in Non-diabetic Individuals?
Current Pharmaceutical Design Inhaled Insulin and the Lung
Current Medicinal Chemistry Applying Knowledge of Enzyme Biochemistry to the Prediction of Functional Sites for Aiding Drug Discovery
Current Topics in Medicinal Chemistry Preventing Atherosclerosis with Angiotensin-Converting Enzyme Inhibitors: Emphasis on Diabetic Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders The Relationship between Age-Related Kidney Dysfunction and Framingham Risk Score in Healthy People in China
Current Aging Science Interactive Effect of Cigarette Smoking and Gene Variants for Predisposing to Cardiovascular Disease
Current Pharmaceutical Design Difficulties in Describing Allergic Disease Modulation by Pre-, Pro- and Synbiotics
Current Pharmaceutical Design Effects of Onion Extract on Endogenous Vascular H2S and Adrenomedulin in Rat Atherosclerosis
Current Pharmaceutical Biotechnology Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine Pharmacotherapy and Prevention of Vascular Dementia
CNS & Neurological Disorders - Drug Targets Cardiovascular Effects of Omega-3 Free Fatty Acids.
Current Vascular Pharmacology Analysis of Protein Glycation Products by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry
Current Medicinal Chemistry The Roles of the PDZ-containing Proteins Bridge-1 and PDZD2 in the Regulation of Insulin Production and Pancreatic Beta-Cell Mass
Current Protein & Peptide Science Diacylglycerol Kinases as Emerging Potential Drug Targets for a Variety of Diseases
Current Drug Targets